Shi Meilin, Cao Menghan, Song Jun, Liu Qinghua, Li Hailong, Meng Fei, Pan Zhenqiang, Bai Jin, Zheng Junnian
Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical College, 84 West Huaihai Road, Xuzhou, 221002, Jiangsu Province, China.
School of Medical Imaging, Xuzhou Medical College, Xuzhou, Jiangsu, China.
Mol Cancer. 2015 Mar 26;14:66. doi: 10.1186/s12943-015-0332-2.
PinX1 (PIN2/TRF1-interacting telomerase inhibitor 1) was suggested to be correlated with tumor progression. This study was designed to evaluate the role of PinX1 in human breast cancer.
To evaluate the function of PinX1 in breast cancer, we used a tissue microarray (TMA) of 405 human breast cancer patients and immunohistochemistry to analyze the correlation between PinX1 expression and clinicopathologic variables and patient survival. We also detected the abilities of cell migration and invasion in breast cancer by performing cell migration and invasion assay, gelatin zymography and western blot analysis. Lastly, we set up the nude mice model by Tail vein assay to exam the functional role of PinX1 in breast cancer metastasis.
We found that low PinX1 expression was associated with lymph node metastasis (P = 0.002) and histology grade (P = 0.001) in patients, as well as with poorer overall and disease-specific survival (P = 0.010 and P = 0.003, respectively). Moreover, we identified that PinX1 inhibited the migration and invasion of breast cancer by suppressing MMP-9 expression and activity via NF-κB-dependent transcription in vitro. Finally, our mice model confirmed that PinX1 suppressed breast cancer metastasis in vivo.
Our data revealed that low PinX1 expression was an independent negative prognostic factor for breast cancer patients. These findings suggested that PinX1 might be function as a tumor metastasis suppressor in the development and progression of breast cancer by regulating the NF-κB/MMP-9 signaling pathway, and might be a prognostic marker as well as a therapeutic target for breast cancer.
PinX1(PIN2/TRF1相互作用端粒酶抑制剂1)被认为与肿瘤进展相关。本研究旨在评估PinX1在人类乳腺癌中的作用。
为评估PinX1在乳腺癌中的功能,我们使用了405例人类乳腺癌患者的组织芯片(TMA),并通过免疫组织化学分析PinX1表达与临床病理变量及患者生存之间的相关性。我们还通过细胞迁移和侵袭实验、明胶酶谱分析和蛋白质印迹分析检测了乳腺癌细胞的迁移和侵袭能力。最后,我们通过尾静脉注射法建立裸鼠模型,以研究PinX1在乳腺癌转移中的功能作用。
我们发现,PinX1低表达与患者的淋巴结转移(P = 0.002)、组织学分级(P = 0.001)相关,也与较差的总生存期和疾病特异性生存期相关(分别为P = 0.010和P = 0.003)。此外,我们发现PinX1在体外通过NF-κB依赖的转录抑制MMP-9的表达和活性,从而抑制乳腺癌细胞的迁移和侵袭。最后,我们的小鼠模型证实PinX1在体内可抑制乳腺癌转移。
我们的数据表明,PinX1低表达是乳腺癌患者独立的负性预后因素。这些发现提示,PinX1可能通过调节NF-κB/MMP-9信号通路在乳腺癌的发生和发展过程中发挥肿瘤转移抑制因子的作用,可能成为乳腺癌的一个预后标志物和治疗靶点。